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β-Endorphin plays a major role in the amelioration of insulin resistance. The present study documents that myricetin
(3,5,7,3 ,4  ,5  -hexahydroxyﬂavone) ameliorates insulin resistance by enhancingβ-endorphin production in insulin-resistantrats.
The rats were induced for insulin resistance by feeding them a diet containing 60% fructose for 6 weeks. The degree of insulin
resistancewasmeasured by the homeostasismodel assessmentofbasalinsulinresistance(HOMA-IR).The plasmalevels ofinsulin
and β-endorphin were measured by an enzyme-linked immunosorbent assay. The insulin receptor-related signaling mediators in
the soleus muscles of rats were evaluated by immunoprecipitation or immunoblotting. Myricetin was injected daily (1mgkg−1
per injection, thrice daily) for 14 days. Consequently, the high-glucose plasma levels in fructose-fed rats decreased signiﬁcantly
concomitant with an increase in plasma β-endorphin. The reduction of the elevated HOMA-IR index following treatment with
myricetinwassubsequentlyinhibitedbytheadministrationofβ-funaltrexaminehydrochloride(β-FNA) atdosessuﬃcienttoblock
μ-opioidreceptors (MOR).Themyricetin treatment wasalsoobservedtoaﬀectthephosphorylationoftheinsulinreceptor, insulin
receptor substrate-1, Akt and Aktsubstrate of 160kDa,with subsequent eﬀects on glucose-transporter subtype 4 translocation,all
of which were blocked by β-FNA pretreatment. These results indicated that enhancement of β-endorphin secretion, which in turn
leads to peripheral MOR activation, is involved in the action ofmyricetin onthe ameliorationofimpaired signalingintermediates
downstream of insulin receptors.
1.Introduction
Myricetin (3,5,7,3 ,4  ,5  -hexahydroxyﬂavone) is a ﬂavonoid
commonlyfoundintea,berries,fruits,vegetablesandmedic-
inal herbs. Myricetin has been shown to possess antiox-
idative and cytoprotective properties [1, 2]. A therapeutic
eﬀect of myricetin in patients with cardiovascular diseases
associated with diabetes mellitus has also been reported
[1, 2]. An insulinomimetic eﬀect of myricetin on lipoge-
nesis and glucose transport in the adipocytes of rats with
noninsulin-dependent diabetes mellitus has been observed
[3]. Myricetin has been found to reduce hyperglycemia in
diabetic rats, possibly through its ability to increase hepatic
glycogen synthesis and to normalize hypertriglyceridemia
[4]. Myricetin has also demonstrated the ability to improve
glucose utilization, lowering plasma-glucose levels in a type
1 diabetes-like animal model [5]. Furthermore, myricetin
displays the characteristics of rosiglitazone, demonstrating
improved glucose utilization and ameliorating the impaired
insulin-signaling pathwayininsulin-resistant ratsinducedby
the high intake of fructose. However, unlike rosiglitazone, it
doesnotcauseanincrease inbodyweight[6],suggestingthat
myricetincanserveasatherapeuticadjunctforthetreatment
of insulin-resistant patients and/or for patients susceptible
to the thiazolidinediones-induced side eﬀects of weight gain
and edema [7].
Insulin resistance in genetically obese Zucker rats
was shown to improve upon exercise, and β-endorphin
is implicated in this exercise-induced improvement of
insulin resistance [8]. The β-endorphin has been shown to2 Evidence-Based Complementary and Alternative Medicine
reverse the impaired insulin-stimulated glucose disposal in
insulin-resistant rats induced by a fructose-rich diet [9].
Furthermore, it was documented that activation of μ-opioid
receptors (MOR) by loperamide reversed insulin-stimulated
glucose uptake impaired by cytokines in C2C12 cells, with
a marked recovery of insulin signaling [10], and can
ameliorate defective postreceptor insulin signaling, reversing
the impairment of insulin-stimulated glucose utilization in
obese Zucker rats [11]. A direct role has been demonstrated
forperipheralMORactivationintheimprovementofinsulin
resistance induced by a high intake of fructose, as this
improvement is more rapid in MOR knockout mice than
in wild-type mice [12]. These results led to the idea that
activation of MOR on insulin-targeted organs may have a
beneﬁcial eﬀect in reducing insulin resistance.
We have shown that activation of MORs on the soleus
muscle, in response to increased endogenous β-endorphin
secretion, is essential to the plasma glucose-lowering action
of myricetin in diabetic rats lacking insulin [13]. This study
was undertaken to ascertain whether elevation of circulating
β-endorphin and/or activation of peripheral MORs could
mediate the action of myricetin and ameliorate insulin
resistance.
2.Methods
2.1. Materials. Standard rat chow containing 60% vegetable
starch, 5% fat and 18% protein (Cat. #2018) and fructose-
rich rat chow containing 60% fructose, 5% fat and 18%
protein (Cat. #TD 89247) were obtained from Harlan Teklad
(Madison,WI,USA).Myricetin(purity>96%;Cat.#M6760)
and protein A-sepharose beads were purchased from Sigma-
Aldrich, Inc. (St. Louis, Missouri, USA). β-funaltrexamine
hydrochloride (β-FNA; Cat. #0926) was purchased from
Tocris Bioscience (Bristol, UK). The diagnostic kit used for
determination of plasma glucose levels (Cat. #COD12503)
was purchased from BioSystem (Costa Brava, Barcelona,
Spain). The rat insulin enzyme-linked immunosorbent assay
(ELISA) kit was obtained from LINCO Research, Inc. (St.
Charles, MO, USA; Cat. #EZRMI-13K). The ELSA kit
used for assaying β-endorphin-like immunoreactivity (BER)
was obtained from Peninsula Laboratories Inc. (Belmont,
CA, USA; Cat. #T-4040). The kit used for the protein
dye-binding assay was purchased from Bio-Rad Labora-
tories (CA, USA). Anti-insulin receptor (IR) β-subunit
(Cat. #MS-634 for immunoprecipitation; Cat. #MS-636 for
western blotting), anti-insulin receptor substrate (IRS)-1
(Cat. #MS-630) and anti-phosphotyrosine (Cat. #MS-445)
antibodies were obtained from NeoMarkers (Fremont, CA,
USA). Anti-p85 subunit of phosphatidylinositol (PI) 3-
kinase (p85) (Cat. #4292), anti-Akt (Cat. #9272), anti-
phospho-Ser473Akt (Cat. #9271), anti-phospho-Thr308Akt,
anti-phospho-(Ser/Thr) Aktsubstrate (Cat.#9611)and anti-
glucose-transporter subtype 4 (GLUT 4) (Cat. #2299) anti-
bodies were acquired from Cell Signaling Technology, Inc.
(Beverly, MA, USA). The anti-AS160 (Rab GAP) antibody
was purchased from Upstate (Charlottesville, VA; Cat. #07-
741). ECL Western Blotting Systems were obtained from
Amersham Corp. (Braunschweig, Germany). Bovine insulin
was obtained from NovoNordisk (Bagsvaerd, Denmark). All
other reagents were obtained from standard sources.
2.2. Animal Models. Eight-week-old, male Wistar rats were
obtained from the National Laboratory Animal Center
(Taipei, Taiwan). They were maintained in a temperature-
controlled room (25 ± 1◦C) and kept on a 12:12 light-
dark cycle (light on at 06:00h) in our animal center. Rats
receivedthefructose-rich ratchowforsixadditionalweeksto
induce insulin resistance [6]. Food and water were available
ad libitum. All animal procedures were performed according
to the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health as well as the guidelines of
the Animal Welfare Act.
2.3. Treatment Procedures. The fructose-fed rats were
divided into three experimental groups. It has been doc-
umented that fructose-fed rats receiving intravenous (i.v.)
injections of myricetin in the lateral tail vein every 8h,
thrice daily (at 06:00., 14:00 and 22:00h) at 1mgkg−1 per
injection for 14 consecutive days were found to demon-
strate eﬀectively ameliorated insulin resistance [6]. Thus,
one group of fructose-fed rats was given i.v. injections of
1mgkg −1 myricetin according to the treatment regimen
d e s c r i b e da b o v e .T h es e c o n dg r o u po ff r u c t o s e - f e dr a t s
received injection of myricetin plus β-FNA [14]. β-FNA was
i.v. injected 30min prior to administration of myricetin. The
remaining fructose-fed rats given the same volume of vehicle
(saline) used todissolvethe testmedicationswere considered
as the vehicle-treated group. The injection volume was
controlled in that 1mLkg−1 was routinely administered. The
injection was given slowly to avoid as much pain and shock
as possible and thereby helping to exclude non-predictive
outcomes. The rats were maintained on a fructose diet
during the treatment period. Water was made available ad
libitum throughout the experiment.
After a 2-week treatment, blood samples (0.1mL) were
collected from the tail vein of rats when deeply anes-
thetized by sodium pentobarbital (30mgkg−1, intraperi-
toneal). Blood samples were used to evaluate glucose, insulin
and β-endorphin plasma levels. The homeostasis model
assessment of basal insulin resistance (HOMA-IR) was used
to calculate an index from the product of the fasting
concentrations of plasma glucose (mmolL−1)a n dp l a s m a
insulin (μUmL −1) divided by 22.5 [15]. Lower HOMA-IR
values indicated greater insulin sensitivity, whereas higher
HOMA-IR values indicated lower insulin sensitivity (insulin
resistance).
2.4. Plasma Analysis. Plasma glucose concentrations were
measured using the glucose oxidase method by means of
a commercially available kit. The ELISA technique was
employed to quantify the plasma levels of insulin and BER.
All samples were analyzed in triplicate.
2.5. In VivoInsulin ReceptorActivation. To assess thechanges
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anesthetized with sodium pentobarbital at the end of the 2-
week treatment period. A bolus of insulin (10Ukg−1)w a s
then injected into the portal vein, as described previously
[6]. Approximately 120s after insulin injection, rats were
sacriﬁced and the soleus muscle was immediately extirpated,
washed with cold phosphate buﬀer and cut into 200–300mg
portions, which were then stored separately at −80◦Cf o r
subsequent experiments.
2.6. Muscle Processing. Cytosol and membrane fractions
were prepared according to the previous method [6,
16]. Brieﬂy, muscles used for measuring insulin signaling
were weighed while still frozen and homogenized (Poly-
tron, Brinkmann Instruments, Inc., Westbury, NY, USA)
in 0.4mL homogenizing buﬀer containing 250mmolL−1
sucrose, 20mmolL−1 Tris (pH: 7.5), 2mmolL−1 ethylenedi-
aminetetraacetic acid (EDTA), 0.5mmolL−1 ethylene glycol
tetraacetic acid (EGTA), 20μgmL −1 leupeptin, 10μgmL −1
aprotinin, 174.2μgL −1 phenylmethylsulfonyl ﬂuoride and
20mmolL−1 dithiothreitol. The homogenate was cen-
trifuged at 100000g for 1h at 4◦C. The supernatant
(cytosolic extract) was transferred to a tube kept on ice,
whereasthepelletwasresuspendedin0.45mLhomogenizing
buﬀer containing 5% Triton X-100. The resuspended pellet
fraction was then centrifuged at 14000g for 5min at 4◦C,
and the pellet was discarded. The supernatant from this spin
constitutes the membrane extract. Protein concentrations
were determined by the BioRad protein dye-binding assay.
The supernatant was stored at −80◦C until used in immuno-
precipitation and Western immunoblotting.
2.7. Immunoprecipitation. Muscle lysates (500μg) were sub-
jected to immunoprecipitation with the anti-IR β-subunit,
anti-IRS-1 or anti-AS160 (Rab GAP) antibody at 4◦C
overnight, followed by shaking with protein A-Sepharose
beads for 1h. The bead-Protein A-antibody-antigen com-
plexes were precipitated by brief centrifugation. The pellets
were washed thrice in ice-cold buﬀer (0.5% Triton X-
100, 100mmolL−1 Tris, pH: 7.4, 10mmolL−1 EDTA and
2mmolL−1 sodium vanadate), resuspended in Laemmli
sample buﬀer and boiled for 5min. The sepharose beads
were precipitatedbybriefcentrifugation and thesupernatant
prepared for sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE, 10% acrylamide gel) using a
Bio-Rad Mini-Protein II system (55 and 130V during
the stacking and separation phases, respectively). Protein
was transferred to a polyvinylidene diﬂuoride (PVDF)
membrane using a Bio-Rad Trans-Blot system (2h at
20V in 25mmolL−1 Tris, 192mmolL−1 glyceine and 20%
methanol (MeOH)). Following transfer, the membrane
was probed with anti-IR β-subunit, anti-IRS-1 and anti-
phosphotyrosine antibodies.
2.8. Immunoblotting. Equal amounts of protein (50μg)
were prepared from muscle homogenates, subjected to
SDS-PAGE, transferred to PVDF membrane as described
above and probed with anti-PI3-kinase p85, anti-Akt and
anti-GLUT 4 antibodies according to the manufacturer’s
instructions. Protein phosphorylation of Akt was mea-
sured using the anti-phospho-Ser473Akt and anti-phospho-
Thr308Akt antibodies. Phosphorylation of Akt substrate of
160 kDa (PAS-AS160) was detected using the anti-phospho-
(Ser/Thr) Akt substrate antibody. PAS-AS160 recognizes Akt
phosphorylation-motif peptide sequences (RXRXXpT/S).
After three 5-min washes in Tris Buﬀered Saline Tween-
20 (TBST; 20mmolL−1 Tris-HCl, pH: 7.5, 150mmolL−1
sodium chloride (NaCl) and 0.05% Tween 20), membranes
were incubated with the appropriate peroxidase-conjugated
secondary antibodies. The membranes were then washed
thrice in TBST and visualized on X-ray ﬁlm using the
ECL Western Blotting System. Densities of the obtained
immunoblots were quantiﬁed using a laser densitometer.
The mean value for samples from the vehicle-treated group
on each immunoblot, expressed in densitometry units, was
adjusted to a value of 1. All experimental sample values were
then expressed relative to this adjusted mean value.
2.9. Statistical Analysis. Data are expressed as the mean ±
SEM for each group of animals at the number indicated in
the tables. Statistical diﬀerences among groups were deter-
mined using two-way repeated-measures analysis of variance
(ANOVA). Dunnett range post hoc comparisons were used
to determine the source of signiﬁcant diﬀerences where
appropriate. A P-value < .05 was considered statistically
signiﬁcant.
3.Results
3.1. General Characteristics of Fructose-Fed Rats. Following
the injection of myricetin, plasma glucose levels in fructose-
fed rats fell to a value signiﬁcantly lower than in the
vehicle-treated group (P < .05), showing a plasma glucose-
lowering activity of 18.1 ± 3.2% (Table 1). Meanwhile, an
elevation of the plasma BER level in fructose-fed rats was
observed following myricetin treatment (Table 1). In the
presenceofβ-FNA(10μgkg −1),theplasma glucose-lowering
action of myricetin in fructose-fed rats was eliminated to
approach the values of the vehicle-treated group (Table 1).
Myricetin-induced secretion of plasma BER was unaﬀected
in fructose-fed rats pretreated with β-FNA at any dosage
(Table 1). Additionally, the HOMA-IR score in fructose-
fed rats receiving 2 weeks of myricetin treatment showed
ad e c r e a s eo f∼70% of the score observed in the vehicle-
treated group (Table 1). Pretreated fructose-fed rat with β-
FNA (10μgkg −1) was observed to abolish this myricetin-
induced reduction of the HOMA-IR (Table 1).
3.2. Protein Levels and Degrees of Insulin Receptor (IR) and
Insulin Receptor Substrate (IRS)-1 Tyrosine Phosphorylation.
There were no signiﬁcant diﬀerences in the expression of
IR protein in the soleus muscle of fructose-fed rats between
any of the groups (Figure 1). Two-week myricetin treatment
slightly elevated the levels of IRS-1 protein expression in the
soleus muscles of fructose-fed rats, and this was antagonized
by β-FNA (Figure 1). The quantiﬁcation ofthe immunoblots
is summarized in Table 2.4 Evidence-Based Complementary and Alternative Medicine
Table 1: General characteristics of fructose-fed rats after 14-day treatment with myricetin or myricetin plus MOR antagonist.
Vehicle Myricetin Myricetin + β-FNA
(1μgkg −1)
Myricetin + β-FNA
(5μgkg −1)
Myricetin + β-FNA
(10μgkg −1)
Plasma glucose (mg dl−1) 137.2 ± 5.8 112.4 ± 5.1b 118.4 ± 4.9a 125.3 ± 5.6 134.5 ± 6.2
Plasma insulin (μUmL −1) 53.8 ± 6.2 51.6 ± 4.7 51.8 ± 5.2 52.3 ± 6.3 53.4 ± 5.9
Plasma BER (pgmL−1) 49.3 ± 5.2 93.5 ± 7.2b 92.8 ± 5.7 92.5 ± 6.1 93.0 ± 5.6
HOMA-IR score 18.2 ± 1.4 13.6 ± 1.6a 14.8 ± 2.1a 16.2 ± 1.7 17.7 ± 2.0
Fructose-fed rats received i.v. injection of myricetin(1mgkg−1), thrice daily for 14 days. β-FNA was i.v. injected 30min prior to administration of myricetin.
The vehicle used to dissolve the tested drugs was given at the same volume. Values (mean ± SEM) were obtained from seven rats. aP < .05 and bP < .01
compared to the values of the vehicle-treated group, respectively.
Table 2: Quantiﬁcation of the protein expression of speciﬁc insulin receptor-related signaling mediators in soleus muscles of fructose-fed
rats receiving 14-day treatment with myricetin or myricetin plus MOR antagonist.
Relative units Fructose-fed rats
Vehicle Myricetin Myricetin + β-FNA
IR 1.00 ± 0.07 1.04 ± 0.06 0.99 ± 0.05
IRS-1 1.01 ± 0.06 1.18 ± 0.05a 1.02 ± 0.08
p85 1.01 ± 0.05 1.21 ± 0.07a 1.08 ± 0.04
Akt 1.00 ± 0.08 1.15 ± 0.06a 0.96 ± 0.09
AS160 1.01 ± 0.07 1.17 ± 0.04a 1.03 ± 0.06
Fructose-fed rats received i.v. injection of myricetin (1mgkg−1), thrice daily for 14 days. β-FNA (10μgkg −1) was i.v. injected 30min prior to administration
of myricetin. The vehicle used to dissolve the tested drugs was given at the same volume. Values (mean ± SEM) were obtained from 5 rats. aP < .05 represents
the level of signiﬁcance compared to the values of the vehicle-treated group.
IR
IRS-1
p85
Akt
AS160
β-FNA
−
−−
++
+
Myricetin
Figure 1: Protein expression of insulin receptor-related signaling
mediatorsinthesoleusmusclesoffructose-fed ratsreceiving 14-day
treatment with myricetin (1mgkg−1 per i.v. injection, thrice daily)
or myricetin plus β-FNA. β-FNA (10μgkg −1 per injection) was i.v.
injected 30min prior to administration of myricetin. Rats that did
not receive any treatment were given the same volume of vehicle
used to dissolve the test medications. Findings were reproduced on
four separate occasions. The quantiﬁcation of the data is shown in
Table 2.
Under non-insulin stimulating conditions, the degree
of tyrosine phosphorylation of IR and IRS-1 in the soleus
muscles of fructose-fed rats was slightly elevated following
the2-weekmyricetin treatment,butthesemyricetin-induced
eﬀects were not observed in rats pretreated with β-FNA
(Figure 2). The extent of IR and IRS-1 tyrosine phosphory-
lation in the soleus muscles of fructose-fed rats in response
to insulin stimulation was markedly elevated in the 2-week
myricetin-treated group. Myricetin failed to induce similar
changes in IR and IRS-1 tyrosine phosphorylation in the
soleus muscles of fructose-fed rats pretreated with β-FNA
(Figure 2).
3.3. Changes in Protein Levels and Amount of the p85 Subunit
of PI3-Kinase Associated with IRS-1. Two-week treatment of
fructose-fed rats with myricetin improved the expression of
the p85 subunit of PI3-kinase in the soleus muscles, and this
eﬀect was abolished by β-FNA pretreatment (Figure 2). The
quantiﬁcation of the immunoblots is summarized in Table 2.
Following a 2-week myricetin treatment, thebasal degree
of p85 associated with IRS-1 in the soleus muscles of
fructose-fed rats was slightly higher than the levels of
the vehicle-treated controls, and myricetin failed to induce
similar changes in fructose-fed rats pretreated with β-FNA
(Figure 3) .T h eh i g h e rd e g r e eo fi n s u l i n - s t i m u l a t e dp 8 5
associated with IRS-1 in myricetin-treated rats was clearly
prevented by β-FNA pretreatment (Figure 3).
3.4. Protein Levels and Degree of Akt and Akt Substrate
of 160kDa (AS160) Phosphorylation. After 2 weeks of
myricetin treatment, the basal protein levels of Akt and
AS160 in the soleus muscles of fructose-fed rats were higher
to those of their vehicle-treated group, and this diﬀerence
was eliminated by β-FNA pretreatment (Figure 2). The
quantiﬁcation of the immunoblots is summarized in Table 2.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Tyrosine phosphorylation (pY) of insulin receptor
(IR)(a) and insulin receptor substrate (IRS)-1(b) in the soleus
muscles of fructose-fed rats receiving 14-day treatment with
myricetin (1mgkg−1 per i.v. injection, thrice daily) or myricetin
plus β-FNA. β-FNA (10μgkg −1 per injection) was i.v. injected
30min prior to administration of myricetin. Rats that did not
receive any treatment were given the same volume of vehicle used
to dissolve the test medications. Findings were reproduced on four
separate occasions. Quantiﬁcation of protein levels are expressed as
mean ± SEM (n = 5 per group) in each column. aP < .05 represents
the level of signiﬁcance compared to the basal values of the vehicle-
treated group.
It was observed that the degree of basal phosphory-
lation of Akt (Thr308/Ser473) and AS160 was increased in
the soleus muscles of fructose-fed rats receiving 2-week
myricetin treatment (Figure 4) .T h ed e g r e eo fi n s u l i n -
stimulated phosphorylation ofAkttyrosine (Thr308)an dAkt
serine (Ser473) was also signiﬁcantly elevated by myricetin
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Figure 3: The amount of the p85 subunit of PI3-kinase associated
with IRS-1(p85/IRS-1) in the soleus muscles of fructose-fed rats
receiving 14-day treatment with myricetin (1mgkg−1 per i.v.
injection, thrice daily) or myricetin plus β-FNA. β-FNA (10μgkg −1
per injection) was i.v. injected 30min prior to administration of
myricetin. Rats that did not receive any treatment were given the
same volume of vehicle used to dissolve the test medications. Find-
ings were reproduced on four separate occasions. Quantiﬁcation of
protein levels expressed as mean ± SEM (n = 5 per group) in each
column. aP < .05 and bP < .01 represent the level of signiﬁcance
compared to the basal values of the vehicle-treated group.
to ∼1.8-fold and 2.2-fold relative to that of the vehicle-
treated controls, respectively (Figure 4(a)). Furthermore,
the degree of insulin-stimulated AS160 phosphorylation in
the soleus muscles of myricetin-treated fructose-fed rats
was markedly higher than the value of their vehicle-treated
group (Figure 4(b)). These myricetin-induced eﬀects were
eliminated by β-FNA pretreatment (Figure 4).
3.5. Insulin-Stimulated Glucose-Transporter Subtype 4 (GLUT
4) Translocation. At the termination ofthe 2-week myricetin
treatment, insulin-stimulated GLUT 4 protein expression in
the membrane fraction of the soleus muscles from fructose-
fed rats was increased ∼1.8-fold of that observed in their
vehicle-treated group; conversely, the protein levels in the
cytosolic fraction of the same samples decreased to 60% of
that observed in the vehicle-treated controls (Figure 5). The
myricetin-mediated changes in insulin-stimulated GLUT 4
translocation were reversed by β-FNA pretreatment (Fig-
ure 5).
4.Discussion
In the present study, a 2-week treatment regimen with
myricetin (1mgkg−1 per i.v. injection, thrice daily) was
found to signiﬁcantly increase plasma BER in a manner
that paralleled the lowering of plasma glucose in rats fed
for 6 weeks with fructose chow, highlighting the possibility
that increased plasma BER and the reduction of plasma6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Phosphorylation of Akt (a) and AS160 (b) in the soleus muscles of fructose-fed rats receiving 14-day treatment with myricetin
(1mgkg−1 per i.v. injection, thrice daily) or myricetin plus β-FNA. β-FNA (10μgkg −1 per injection) was i.v. injected 30min prior to
administration of myricetin. Rats that did not receive any treatment were given the same volume of vehicle used to dissolve the test
medications. Findings were reproduced on four separate occasions. Quantiﬁcation of protein levels expressed as mean ± SEM (n = 5p e r
group) in each column. aP < .05 and bP < .01 represent the level of signiﬁcance compared to the basal values of the vehicle-treated group.
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Figure 5: Insulin-stimulated GLUT 4 protein expression in the membrane (a) and cytosolic (b) fractions in the soleus muscles of fructose-
fed rats receiving 14-day treatment with myricetin (1mgkg−1 per i.v. injection, thrice daily) or myricetin plus β-FNA. β-FNA (10μgkg −1
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levels expressed as mean ± SEM (n = 5 per group) in each column. aP < .05 represents the level of signiﬁcance compared to the values of the
vehicle-treated group.Evidence-Based Complementary and Alternative Medicine 7
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Figure6: Thepossiblemechanismsofmyricetin actionontheameliorationofdefective post-receptor insulinsignalingin theskeletalmuscle
of fructose-fed rats.
glucoseconcentrations are related phenomena in thismodel.
Although the eﬀect of myricetin on the lowering of plasma
glucose was suppressed by blockade of MOR via β-FNA
pretreatment, this antagonist had no inﬂuence on the
myricetin-induced secretion of plasma BER. As illustrated
by the ﬁndings that myricetin promoted an increase in
plasma BER concurrent with a lowering of plasma glucose
concentrations, a direct eﬀect of this ﬂavonol on glucose
homeostasis in insulin-resistant rats seems unlikely.
Inhumans andothermammals, skeletalmusclenormally
accounts for ∼75% of whole-body, insulin-stimulated glu-
cose transport [17]. An impaired ability of skeletal muscles
to respond to insulin is, therefore, disruptive to systemic
glucose homeostasis. Actually, the increase in insulin action
on skeletal muscle is likely to be related to increased protein
expression and/or functional activity of several key com-
ponents of the insulin signal-transduction pathway; defects
in the insulin-signaling cascade, which lead to impaired
glucose utilization, are believed to play a key role in the
pathogenesis of insulin resistance [18]. It is conceivable
that IRS-1 tyrosine phosphorylation (in response to insulin
stimulation)generallyincreases theassociation ofIRS-1with
the p85 subunit of PI3-kinase, resulting in increased PI3-
kinase activity. In turn, this would lead to the activation
of serine/threonine kinase Akt (protein kinase B) and,
ultimately, accelerated rates of GLUT 4 translocation, such
that GLUT 4 manifests predominantly at the cell surface
and enhances insulin-stimulated glucose disposal [19]. It
has been documented that the action of insulin on glucose
uptake and metabolism is much greater in skeletal muscles
composed primarily of oxidative ﬁbers (e.g., the soleus) as
compared to glycolytic ﬁbers (e.g., the epitrochlearis and
extensor digitorum longus), even though the soleus muscle
represents a small portion of the total muscle mass [20].
Activation of MOR located on the soleus muscle, resulting
in reversal of the impairment of insulin-stimulated glucose
disposal in obese Zucker rats, has been documented; this
improvement in insulin resistance was associated with the
amelioration of the post-receptor insulin-signaling cascade,
including downstream eﬀectors of the PI3-kinase signaling
pathway involved in glucose-transporter translocation [11].
We found that increasing the doses of β-FNA negatively
correlated with the eﬀect of myricetin on the reduction of
higher HOMA-IR in fructose-fed rats, although the higher
plasma levels of BER were still apparent in the myricetin-
treated group. This raised the possibility that an elevation
of circulating β-endorphin and/or activation of peripheral
MOR might be the mechanisms by which myricetin amelio-
rates the defective insulin action. With this in mind, soleus
muscle samples were prepared from all animals after insulin
stimulation.
A substrate of Akt has been identiﬁed that may provide
a link between insulin signaling and GLUT 4 traﬃcking.
This protein, AS160, has a GAP homology domain and is
phosphorylated by Akt in response to insulin [21]. In this
study we showed that myricetin treatment had clear eﬀects
on the IRS-1/PI3-kinase/Akt/AS160 signaling cascade (at
both the protein expression and phosphorylation levels) and
subsequent GLUT 4 traﬃcking, which were all suppressed by
MOR antagonism. These ﬁndings suggested that the eﬀect
of myricetin on the improvement of post-receptor insulin
signaling might be dependent on the activation of MOR
located on peripheral insulin-sensitive tissues, such as skele-
tal muscle. Additionally, these results supported the essential
role of opioids during glucose homeostasis. Furthermore,
opioids or opioid receptor activation, especially of the μ-
subtype, may have key functions in glycemic control.
Although β-endorphin is released with adrenocorti-
cotropichormonefromthepituitarygland[22],thepituitary
gland-independent release of endogenous opioids occurs in
other organs, such as the adrenal gland [9, 23]. We provided
new evidence that activation of α1-adrenoceptors on the
adrenal gland may increase β-endorphin secretion via the
phospholipase C-protein kinase C pathway, which in turn
activates peripheral MOR to modify glucose metabolism-
associated genes, thereby leading to improved peripheral8 Evidence-Based Complementary and Alternative Medicine
glucose utilization and decreased hepatic gluconeogenesis
for amelioration of severe hyperglycemia in type 1-like
diabetes [24]. Secretion of β-endorphin from the adrenal
gland was observed to be essential to the plasma glucose-
lowering action of myricetin in streptozotocin-induced
(STZ)-diabetic rats [13]. It is not clear if myricetin-induced
β-endorphin secretion in fructose-fed rats is mediated
by pituitary gland-dependent or -independent pathways;
however, it was strongly demonstrated that the myricetin-
mediated action converged at a point between the down-
stream targetsoftheperipheralMORandtheIRS-PI3-kinase
signaling pathway, subsequently aﬀecting insulin-induced
GLUT 4 translocation (Figure 6).
A widely recommended approach for the control of
hyperglycemia is to administer a parenteral insulin prepa-
ration that provides a constant source of circulating insulin
for 12–24h to augment or replace deﬁcient endogenous
insulin secretion, although insulin resistance is eventually
developed in these insulin-treated patients [25]. The mech-
anisms underlying the concentration- and time-dependent
induction ofinsulin resistance are complexand incompletely
deﬁned. Thus, it is imperative to identify new targets that
can achieve equal and/or superior eﬀects on the control
of glycemia with a reduction in insulin resistance. The
ﬁndings of our study provide new insights into the chemical
c o m p o u n d so rh e r b a lp r o d u c t st h a tm i g h te n h a n c eβ-
endorphin secretion and/or stimulate MOR in peripheral
insulin-sensitive tissue, which mightserve as potentialagents
or adjuvants for targeting glucose metabolism in insulin-
resistant individuals.
5.Conclusion
The survey showed that the action of myricetin on the
amelioration of defective post-receptor insulin signaling,
especially as it related to IRS-1-associated PI3-kinase and
GLUT 4 translocation, required β-endorphin as a mediator
to activate peripheral MOR.
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